| Literature DB >> 28097239 |
Xiangsheng Zuo1, Weiguo Xu1,2, Min Xu1, Rui Tian1, Micheline J Moussalli3, Fei Mao1, Xiaofeng Zheng4, Jing Wang4, Jeffrey S Morris5, Mihai Gagea6, Cathy Eng1, Scott Kopetz1, Dipen M Maru3, Asif Rashid3, Russell Broaddus3, Daoyan Wei7, Mien-Chie Hung8, Anil K Sood9,10,11, Imad Shureiqi1.
Abstract
Peroxisome proliferator-activated receptor-δ (PPARD) is upregulated in many major human cancers, but the role that its expression in cancer cells has in metastasis remains poorly understood. Here, we show that specific PPARD downregulation or genetic deletion of PPARD in cancer cells significantly repressed metastasis in various cancer models in vivo. Mechanistically, PPARD promoted angiogenesis via interleukin 8 in vivo and in vitro. Analysis of transcriptome profiling of HCT116 colon cancer cells with or without genetic deletion of PPARD and gene expression patterns in The Cancer Genome Atlas colorectal adenocarcinoma database identified novel pro-metastatic genes (GJA1, VIM, SPARC, STC1, SNCG) as PPARD targets. PPARD expression in cancer cells drastically affected epithelial-mesenchymal transition, migration, and invasion, further underscoring its necessity for metastasis. Clinically, high PPARD expression in various major human cancers (e.g., colorectal, lung, breast) was associated with significantly reduced metastasis-free survival. Our results demonstrate that PPARD, a druggable protein, is an important molecular target in metastatic cancer.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28097239 PMCID: PMC5214933 DOI: 10.1172/jci.insight.91419
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708